Cargando…
Fluvoxamine for the treatment of COVID-19 – Author's reply
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
The Author(s). Published by Elsevier Ltd.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846598/ https://www.ncbi.nlm.nih.gov/pubmed/35180413 http://dx.doi.org/10.1016/S2214-109X(21)00588-X |
| _version_ | 1784651876714676224 |
|---|---|
| author | Reis, Gilmar Mills, Edward |
| author_facet | Reis, Gilmar Mills, Edward |
| author_sort | Reis, Gilmar |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-8846598 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | The Author(s). Published by Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-88465982022-02-16 Fluvoxamine for the treatment of COVID-19 – Author's reply Reis, Gilmar Mills, Edward Lancet Glob Health Correspondence The Author(s). Published by Elsevier Ltd. 2022-03 2022-02-15 /pmc/articles/PMC8846598/ /pubmed/35180413 http://dx.doi.org/10.1016/S2214-109X(21)00588-X Text en © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Reis, Gilmar Mills, Edward Fluvoxamine for the treatment of COVID-19 – Author's reply |
| title | Fluvoxamine for the treatment of COVID-19 – Author's reply |
| title_full | Fluvoxamine for the treatment of COVID-19 – Author's reply |
| title_fullStr | Fluvoxamine for the treatment of COVID-19 – Author's reply |
| title_full_unstemmed | Fluvoxamine for the treatment of COVID-19 – Author's reply |
| title_short | Fluvoxamine for the treatment of COVID-19 – Author's reply |
| title_sort | fluvoxamine for the treatment of covid-19 – author's reply |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8846598/ https://www.ncbi.nlm.nih.gov/pubmed/35180413 http://dx.doi.org/10.1016/S2214-109X(21)00588-X |
| work_keys_str_mv | AT reisgilmar fluvoxamineforthetreatmentofcovid19authorsreply AT millsedward fluvoxamineforthetreatmentofcovid19authorsreply |